AdvisorShares Investments LLC Makes New $279,000 Investment in Vistagen Therapeutics, Inc. (NASDAQ:VTGN)

AdvisorShares Investments LLC acquired a new position in shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGNFree Report) during the fourth quarter, Holdings Channel reports. The fund acquired 54,311 shares of the company’s stock, valued at approximately $279,000.

A number of other hedge funds have also recently bought and sold shares of the company. Schonfeld Strategic Advisors LLC purchased a new position in shares of Vistagen Therapeutics in the 3rd quarter worth about $726,000. Blair William & Co. IL purchased a new position in shares of Vistagen Therapeutics in the 3rd quarter worth about $446,000. BML Capital Management LLC boosted its holdings in shares of Vistagen Therapeutics by 50.0% in the 4th quarter. BML Capital Management LLC now owns 150,000 shares of the company’s stock worth $771,000 after buying an additional 50,000 shares during the last quarter. Armistice Capital LLC purchased a new position in shares of Vistagen Therapeutics in the 4th quarter worth about $2,457,000. Finally, Raymond James & Associates purchased a new position in shares of Vistagen Therapeutics in the 3rd quarter worth about $52,000. 78.39% of the stock is owned by hedge funds and other institutional investors.

Vistagen Therapeutics Trading Down 1.8 %

Vistagen Therapeutics stock traded down $0.07 during midday trading on Friday, reaching $3.79. The stock had a trading volume of 169,653 shares, compared to its average volume of 240,801. Vistagen Therapeutics, Inc. has a 12 month low of $1.62 and a 12 month high of $24.71. The firm’s 50-day moving average price is $4.60 and its 200 day moving average price is $4.67.

About Vistagen Therapeutics

(Free Report)

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.

Featured Stories

Want to see what other hedge funds are holding VTGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vistagen Therapeutics, Inc. (NASDAQ:VTGNFree Report).

Institutional Ownership by Quarter for Vistagen Therapeutics (NASDAQ:VTGN)

Receive News & Ratings for Vistagen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vistagen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.